AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
May 17, 2024Research and Development AstraZeneca, COVID-19, Immunology, clinical trial
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …
GSK pledges £45m to Fleming Initiative to fight AMR
May 16, 2024Research and Development AMR, Fleming Initiative, GSK, Microbiology, funding
GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative …
NeuroSense partners with PhaseV on upcoming phase 3 ALS trial
May 16, 2024Research and Development NeuroSense, Neurology, als, clinical trials
NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
May 15, 2024Research and Development AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …
FDA approves Roche’s HPV self-collection screening option
May 15, 2024Medical Communications FDA, HPV, Oncology, Roche, cervical cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …
NHS accepts Pfizer’s tafamidis for ATTR-CM treatment
May 14, 2024Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis
NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).
Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment
May 14, 2024Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy
Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …
PharmaTimes Medical & Scientific Excellence Awards and Nursing Industry Excellence Awards are open for entry
May 13, 2024Business Services MSEA, NIEA, PharmaTimes, awards
Both awards are open for entry until 17 May 2024 and the live awards ceremony will take place on 11 …
Sanofi adds €1bn funding for biomanufacturing projects in France
May 13, 2024Business Services Biomanufacturing, Pharmacy, Sanofi, funding, investment
Sanofi has announced that it has made a new investment of at least €1bn for the creation of new bioproduction …
Moderna shares update on RSV vaccine
May 13, 2024Medical Communications FDA, Immunology, Moderna, Vaccine
Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review …
Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate
May 10, 2024Sales and Marketing Pompe disease, Rare Diseases, Shionogi, licensing agreement, maze therapeutics
Japanese pharmaceutical company Shionogi and US-based Maze Therapeutics have finalised an exclusive worldwide license agreement for MZE001, a novel therapeutic …
Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines
May 10, 2024Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement
French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …
AstraZeneca withdraws COVID-19 vaccine Vaxzevria
May 9, 2024Sales and Marketing AstraZeneca, COVID-19, Immunology, thrombosis with thrombocytopenia syndrome
UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in …
Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study
May 9, 2024Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia
Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …
Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet
May 8, 2024Research and Development Hepatology, Mirum Pharmaceuticals, PFIC, The Lancet, clinical trials
Biopharma company Mirum Pharmaceuticals has announced data from its phase 3 MARCH-PFIC study which evaluated maralixibat in patients with progressive …
Circular Genomics reveals study results into predicting patient response to SSRI antidepressant treatment
May 8, 2024Research and Development Circular Genomics, Psychiatry, SSRI, antidepressant treatment, blood assays
US RNA biomarker company Circular Genomics has announced study results highlighting the company’s first blood assay to predict a patient’s …
Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib
May 7, 2024Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration
US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …
Broken String Biosciences and the Francis Crick Institute collaborate on ALS research
May 7, 2024Research and Development Broken String Biosciences, Francis Crick Institute, Neurology, amyotrophic lateral sclerosis, genomics
Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …
AbbVie invests €150m in new R&D facility in Germany
May 3, 2024Research and Development AbbVie, Pharmacy, R&D, facility
AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
May 3, 2024Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
